Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission
Portfolio Pulse from
Capricor Therapeutics has initiated a rolling BLA submission for Deramiocel, targeting Duchenne Muscular Dystrophy Cardiomyopathy, with completion expected by the end of 2024. Promising 3-year data from the HOPE-2 OLE study shows significant improvements in cardiac and skeletal muscle functions. The company raised $86.3 million in a public offering, securing funds to operate into 2027, excluding potential milestone payments from Nippon Shinyaku.
December 06, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Capricor Therapeutics has initiated a rolling BLA submission for Deramiocel, with promising data from the HOPE-2 OLE study. The company raised $86.3 million, ensuring operations are funded into 2027.
The initiation of the rolling BLA submission and the promising data from the HOPE-2 OLE study are positive indicators for Capricor's future prospects. The successful public offering, raising $86.3 million, provides a strong financial position, reducing immediate financial risks and supporting continued operations. These factors are likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100